Here is what Baron Funds has to say about Moderna, Inc. in its Q3 2021 investor letter:
"Moderna, Inc. is a leader in the emerging field of mRNA-based vaccines and therapeutics. Shares performed well for the quarter. Moderna has been one of the most successful companies in the race to develop and provide a COVID-19 vaccine and is focusing on introducing a COVID-19 booster combined with the flu shot. With the COVID-19 vaccine success under its belt, we think Moderna has potential to disrupt the entire biopharmaceutical industry, from infectious disease vaccines to oncology and rare disease treatment."
Though now we are affacted by PFIZER pills in treating COVID19, we can still see it in oncology and rare disease treatment!
精彩评论